Synapse

← Frontiers in Tuberculosis

Papers in Frontiers in Tuberculosis

Page 1 · newest first

  1. Macrophage-state heterogeneity as the basis for host-directed therapy in tuberculosisFrontiers in Tuberculosis · 2026
  2. Rationally tailored antibiotic selection circumvents toxin-mediated evasion of killing in Mycobacterium abscessusFrontiers in Tuberculosis · 2026
  3. Translating drug-resistant tuberculosis surveillance into molecular–biophotonic diagnostic innovation in rural Eastern Cape, South AfricaFrontiers in Tuberculosis · 2026
  4. Adjunctive antimycobacterial and immunomodulatory effects of Allium cepa (pink variety) in a rabbit model of latent-like mycobacterial infectionFrontiers in Tuberculosis · 2026
  5. Secreted proteins of Mycobacterium tuberculosis as therapeutic targets for drug discoveryFrontiers in Tuberculosis · 2026
  6. A Mycobacterium tuberculosis rare variable antigen vaccine reduces lung pathology in hypersusceptible SP140−/− miceFrontiers in Tuberculosis · 2026
  7. Implementation of sequencing-based surveillance for drug-resistant tuberculosis in NigeriaFrontiers in Tuberculosis · 2026
  8. The AcasR-FadD9 regulatory axis modulates iron homeostasis and susceptibility to the anti-mycobacterial compound ACAFrontiers in Tuberculosis · 2026
  9. Using interpretable decision trees to explore TB-HIV integration under data constraints: a proof-of-concept analysisFrontiers in Tuberculosis · 2026
  10. Identification of novel DNA gyrase B inhibitors in Mycobacterium species using integrated computational approachesFrontiers in Tuberculosis · 2026
  11. Differential roles of resident lung macrophages during control of murine alveolar and airway Mycobacterium abscessus infectionFrontiers in Tuberculosis · 2026
  12. Genomic characterization of drug-resistant Mycobacterium tuberculosis complex in western Kenya reveals predominance of isoniazid resistance and discordance with routine susceptibility testingFrontiers in Tuberculosis · 2026
  13. Sigma factor M induces an ESX-4-focused regulon in Mycobacterium abscessusFrontiers in Tuberculosis · 2026
  14. Research overview—2025: integrating scientific progress to accelerate global tuberculosis eliminationFrontiers in Tuberculosis · 2026
  15. Non-tuberculous mycobacteria pulmonary disease in Texas: an analysis of 8 years of hospital discharge dataFrontiers in Tuberculosis · 2026
  16. Readiness assessment as a strategy, not an afterthought: leveraging implementation science to integrate tuberculosis comorbidity care in Pakistan's health systemFrontiers in Tuberculosis · 2026
  17. Evaluation of the performance of promising host transcriptional biosignatures in predicting TB progression during a 1-year prospective cohort study in Indian household contactsFrontiers in Tuberculosis · 2026
  18. Immunometabolic reprogramming of Mycobacterium tuberculosis-responsive memory CD4+ T cell subsets is linked to long-term protective immunityFrontiers in Tuberculosis · 2026
  19. Editorial: Non-tuberculous mycobacteria and bronchiectasisFrontiers in Tuberculosis · 2026
  20. Dose optimization of inhaled tigecycline in humans to overcome inherent adverse events and maximize bacterial clearance using a physiologically-based pharmacokinetic modeling approachFrontiers in Tuberculosis · 2026
  21. Advanced diagnostic methods for nontuberculous mycobacterial infectionsFrontiers in Tuberculosis · 2026
  22. An integrated psycho-social intervention to improve self-efficacy toward TB treatment uptake and infection prevention among patients and family caregivers: a multicentric implementation research study protocolFrontiers in Tuberculosis · 2026
  23. Evaluation of host-immune biomarker signatures as multiplex qPCR diagnostic assays: a pilot study toward meeting WHO target product profiles for TB diagnosis in IndiaFrontiers in Tuberculosis · 2026
  24. Acceptability and feasibility of oral swabs for tuberculosis diagnosis in young children: a qualitative study from Uganda and PeruFrontiers in Tuberculosis · 2026
  25. The “yeast-drop” treatment protocol in the Drosophila model for rapid and cost-effective TB drug testingFrontiers in Tuberculosis · 2026
  26. Evaluation of a short, all oral treatment regimen including bedaquiline, delamanid, linezolid, clofazimine, and pyrazinamide named “Regimen C” for pre-XDR tuberculosis in NigerFrontiers in Tuberculosis · 2026
  27. Bidirectional pathogenesis between non-tuberculous mycobacteria and bronchiectasis: clinical insights, diagnostic challenges and future directions—Perspectives from South AsiaFrontiers in Tuberculosis · 2026
  28. A synthesis of youth activation initiatives and their impact on tuberculosis knowledge, knowledge-seeking, and healthcare-seeking behavior in vulnerable populationsFrontiers in Tuberculosis · 2026
  29. Mycobacteria as evolutionary drivers of host innate immunity: insights from comparing experimental host modelsFrontiers in Tuberculosis · 2025
  30. Implementing TB-Stigma reduction interventions in High Burden Countries: a perspective on a conceptual frameworkFrontiers in Tuberculosis · 2025
  31. Low treatment completion rates reveal gaps in the LTBI care cascade among university studentsFrontiers in Tuberculosis · 2025
  32. Predicting treatment adherence in patients with drug-resistant tuberculosis: insights from socioeconomic, demographic, and clinical factors of patients in the rural Eastern CapeFrontiers in Tuberculosis · 2025
  33. Country-level heterogeneity in MDR-TB drug susceptibility supports country-specific policy developmentFrontiers in Tuberculosis · 2025
  34. Assessment of knowledge, attitudes, and practices regarding TB prevention and treatment among college students in Wuhan, central ChinaFrontiers in Tuberculosis · 2025
  35. Risk factors associated with multidrug-resistant pulmonary tuberculosis in patients over 15 years old: a retrospective case-control studyFrontiers in Tuberculosis · 2025
  36. Targeted transcriptomic analyses of tuberculosis treatment response and outcomes in The GambiaFrontiers in Tuberculosis · 2025
  37. The value of LAM and LprG in extracellular vesicles in the diagnostic and therapeutic field of renal tuberculosisFrontiers in Tuberculosis · 2025
  38. Optimizing use of data and evidence-related tools to complement routine surveillance systems for tuberculosis program planningFrontiers in Tuberculosis · 2025
  39. Prevalence and risk factors of high blood pressure among persons assessed for TB at three health facilities in Lusaka, ZambiaFrontiers in Tuberculosis · 2025
  40. Patterns of Mycobacterium tuberculosis genotypes and resistance mutations in patients with pulmonary multidrug-resistant tuberculosis in Sverdlovsk Oblast, RussiaFrontiers in Tuberculosis · 2025
  41. Predicting fitness in Mycobacterium tuberculosis with transcriptional regulatory network-informed interpretable machine learningFrontiers in Tuberculosis · 2025
  42. Decoding the tuberculosis puzzle: mechanical factors driving disease progressionFrontiers in Tuberculosis · 2025
  43. Tissue-specific T cell profiles in Mycobacterium tuberculosis uninfected IGRA negative and positive individualsFrontiers in Tuberculosis · 2025
  44. Implications of serological, genomic, and epidemiological insights into Mycobacterium tuberculosis mixed infection in a human-managed African elephant (Loxodonta africana)Frontiers in Tuberculosis · 2025
  45. Coexistent anemia modulates systemic inflammation and exacerbates disease severity and adverse treatment outcomes in tuberculosisFrontiers in Tuberculosis · 2025
  46. Analyses of blood-derived host biomarkers for pulmonary tuberculosis diagnosis in human immunodeficiency virus co-infected individuals in sub-Saharan Africa: a systematic review and meta-analysisFrontiers in Tuberculosis · 2025
  47. Ending tuberculosis: challenges and opportunitiesFrontiers in Tuberculosis · 2024
  48. Intersecting epidemics: deciphering the complexities of tuberculosis-diabetes comorbidityFrontiers in Tuberculosis · 2024
  49. Serum-derived host miR-423-5p and miR-378a-3p as molecular markers for severe tuberculosis: a promising prognostic tool for survivalFrontiers in Tuberculosis · 2024
  50. Mycobacterium abscessus pulmonary infection and associated respiratory function in cystic fibrosis-like βENaC miceFrontiers in Tuberculosis · 2024